Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with a five-fold increased risk of stroke (Menke et al, 2010). AF-related stroke is more likely to be fatal or severely disabling compared to other types of stroke, because clots that form in the heart are large and can obstruct large vessels in the brain. This November, the Atrial Fibrillation Association's Global AF Aware Week will draw national attention to: ■ Detecting AF ■ Protecting those with AF from stroke using anticoagulation therapy ■ Correcting irregular rhythms using appropriate treatments ■ Perfecting the patient care pathway (Atrial Fibrillation Association, 2020). Increased clinical understanding and knowledge of recent guidelines among healthcare professionals are necessary to ensure integrated care for those diagnosed with, or suspected of having, AF. The prevalence of AF is increasing and is predicted to double by 2050 (Schnabel et al, 2015), leading to costly and complex hospital admissions and reduced quality of life for patients. Estimates suggest around 1.2 million people in the UK have a diagnosis of AF (Stroke Association, 2017), with a further half a million people currently undiagnosed. The risk of developing AF increases with age and those aged ≥85 years are seven times more likely to have AF than those aged under 55 years (Lane et al, 2017). Other risk factors include diabetes, ethnicity, hypertension, obesity, obstructive sleep apnoea and congestive heart failure. Although it is possible to develop AF without other health conditions, the incidence is higher among complex comorbid populations. Public Health England (2016) have declared that stroke prevention in AF is a national priority. Anticoagulation is a preventative treatment that reduces AF-related stroke risk by two-thirds. In fact, if AF were adequately identified and treated, around 7000 strokes could be prevented every year in England alone, saving approximately 2000 lives (Stroke Association, 2017). AF is greatly associated with heart failure, in part because both conditions have shared mechanisms, leading to neurohormonal and proinflammatory activation, which can induce myocardial inflammation and fibrosis (Staerk et al, 2017). Equally, AF has been shown to be an independent risk factor for cognitive decline and dementia. Symptoms such as palpitations, breathlessness and fatigue affect up to 80% of individuals with AF (Go et al, 2001) and psychological distress is reported in 35%, potentially because of the unpredictable nature of symptoms, or fear of a future thromboembolic event (Walters et al, 2018). Management is complex and attention must be given to the complete patient experience.